Variable | Response, % (n/N) [95% CI] |
---|---|
Overall | 70.7 (29/41) [54.5 to 83.9] |
Probable aspergillosis | 71.8 (28/39) [55.1 to 85.0] |
Proven aspergillosis | 50.0 (1/2) [37.4 to 74.5] |
Combination therapy** | 80.0 (4/5) [28.4 to 99.5] |
Monotherapy | 69.4 (25/36) [51.9 to 83.7] |
First-line therapy*** | 63.6 (7/11) [30.8 to 89.1] |
Second-line therapy | 73.3 (20/30) [54.1 to 87.7] |
Neutropenic status at start of caspofungin therapy | |
Neutrophilic granulocytes < 500/uL | 71.4 (20/28) [51.3 to 86.8] |
Neutrophilic granulocytes ≥ 500/uL | 69.2 (9/13) [38.6 to 90.9] |
Risk factors**** | |
Allogeneic HSCT | 87.5 (7/8) [47.3 to 99.7] |
Acute renal disease | 80.0 (4/5) [28.4 to 99.5] |
Neutropenia at hospitalization | 70.4 (19/27) [49.8 to 86.2] |
Active cancer | 69.2 (27/39) [52.4 to 83.0] |
Immunosuppressive therapy | 68.4 (26/38) [51.3 to 82.5] |
Prior colonization with fungi | 66.7 (4/6) [22.3 to 95.7] |
Autologous HSCT | 50.0 (2/4) [6.8 to 93.2] |